CA-TYLIN
T.Y. Lin International, a globally recognized full-service infrastructure consulting firm, has unveiled a new brand strategy to unify its global operations. The unified brand will connect clients more effectively with TYLin’s multi-discipline global engineering resources to solve infrastructure challenges with innovative and technically advanced solutions at the regional and local levels.
Effective immediately, the company formerly known as T.Y. Lin International will go to market as TYLin . A redesigned logo, also part of the new brand strategy, represents the concept of “Connections” which is at the heart of the TYLin brand story. As a global engineering firm, TYLin connects clients with innovative thinking and global resources to solve their most important infrastructure challenges and enhance how people, places, and communities connect.
The story behind the development of the new TYLin brand and logo can be reviewed on the company’s new website www.TYLin.com .
Historically, TYLin has been recognized for its expertise in designing iconic bridges. Over the years, the company has established itself as a global leader providing engineering services and thought leadership to all segments of the built environment, including aviation, buildings, rail and transit, roads and highways, and water, in addition to bridges. TYLin’s strategic brand positioning highlights the company’s extensive knowledge and experience across all these sectors.
“The refreshed TYLin brand builds on the legacy of innovation created by our founder, Professor Tung-Yen (T.Y.) Lin, and the long-standing relationships we have with our clients around the world,” said Matthew Cummings, PE, TYLin President and Chief Executive Officer. “The rebranding signals our renewed commitment to connect our clients with the technical expertise, innovative thinking, and resources they need so that together we can continue to elevate the lives of people in the communities we serve. It will also foster unity within our firm, streamlining the processes for our employees to connect and collaborate with their global colleagues.”
The new TYLin brand is based on three key pillars: Approachable People who understand clients’ objectives and collaborate to provide seamless delivery of technological solutions through a lifecycle approach; Proven Capabilities and technical excellence; and access to Global Experience with innovative designs in advanced mobility infrastructure, smart buildings, and sustainable water solutions.
Since 1989, TYLin has been part of Dar Group , an international network of professional services firms comprising more than 17,000 staff in over 100 countries. TYLin, the lead brand within Dar’s Global Infrastructure (GI) Pillar, has 3,200 employees in 11 countries.
The strategy to unify the TYLin global brand is part of a phased, multi-year approach that will more closely align all TYLin offices and GI Pillar companies worldwide and facilitate access to global resources to support clients and provide enhanced career development opportunities for employees.
About TYLin:
Founded in 1954, TYLin is a globally recognized, full-service infrastructure consulting firm committed to providing innovative, cost-effective, constructible designs for the global infrastructure market. With 3,200 employees working in 65 offices throughout the Americas, Asia, and Europe, the firm provides support on projects of varying size and complexity. TYLin is a member of Dar Group, a global, privately-owned professional services group, and its industry-leading family of Global Infrastructure companies. For more information about the company, please visit www.tylin.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316006051/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
